Summit Global Investments’s Royalty Pharma RPRX Stock Holding History

Summit Global Investments’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-25,991	Closed	-$735K	–	622
2024 Q3	$735K	Buy	+25,991	New	+$720K	0.05%	294
2024 Q1	–	Sell	-8,915	Closed	-$250K	–	586
2023 Q4	$250K	Sell	8,915 -2,264	-20%	-$62.2K	0.02%	461
2023 Q3	$303K	Sell	11,179 -163,271	-94%	-$4.85M	0.02%	424
2023 Q2	$5.36M	Buy	174,450 +33,069	+23%	+$1.12M	0.36%	72
2023 Q1	$5.09M	Buy	141,381 +3,181	+2%	+$118K	0.39%	70
2022 Q4	$5.46M	Buy	138,200 +581	+0.4%	+$24.3K	0.46%	65
2022 Q3	$5.53M	Sell	137,619 -891	-0.6%	-$38.1K	0.51%	54
2022 Q2	$5.82M	Buy	138,510 +5,545	+4%	+$227K	0.51%	50
2022 Q1	$5.18M	Buy	+132,965	New	+$5.22M	0.38%	75

Other funds holding RPRX

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Summit Global Investments's RPRX Position: Q4 2024 in Review

Summit Global Investments sold out of Royalty Pharma (RPRX) in Q4 2024, closing a stake of 25,991 shares — an estimated $735K sold.

Summit Global Investments first reported a position in RPRX in Q1 2022 and held it in 9 quarters. The position peaked at $5.82M in Q2 2022. 417 funds tracked by Wall St. Rank hold RPRX as of Q4 2024.

Summit Global Investments reported no remaining Royalty Pharma position as of Q4 2024 after selling out during the quarter.
Summit Global Investments sold 25,991 Royalty Pharma shares in Q4 2024, an estimated $735K.
Summit Global Investments first reported a position in Royalty Pharma in Q1 2022 and held it in 9 quarters.
Summit Global Investments's Royalty Pharma position peaked at $5.82M in Q2 2022.
417 funds tracked by Wall St. Rank held Royalty Pharma as of Q4 2024.

Based on Summit Global Investments's 13F filing for Q4 2024, filed 11 Feb 2025.